GSTM1 and colorectal carcinoma: Raman-CRC showed superior overall sensitivity for CRC (95.7% versus 90.9%) compared with recently published FIT performance at a cut-off of ≥10 μg/g of f-Hb (Table 3).7,26 The Raman-CRC test has a sensitivity for early stage I and II CRC of 78.6%.